"Infertility treatment heads first drugs on FDA’s new priority review scheme" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.
After rejecting Replimune’s melanoma drug RP1 this summer, the FDA has accepted the biotech’s resubmission of an approval ...
The FDA has approved Libtayo for the adjuvant treatment of adult patients with CSCC at high risk of recurrence after surgery and radiation.
Eydenzelt is approved for the treatment of patients with neovascular (wet) age-related macular degeneration, macular edema ...
InvestorsHub on MSN
Replimune Shares Skyrocket After FDA Accepts Resubmitted BLA for Melanoma Therapy
Replimune Group Inc (NASDAQ:REPL) surged 60% in premarket trading after the U.S. Food and Drug Administration (FDA) accepted ...
Amgen and AstraZeneca's Tezspire has claimed FDA approval as a treatment for chronic rhinosinusitis with nasal polyps (CRSwNP ...
The drug is the only medicine of its kind proven to help patients with lupus nephritis regain full kidney response, the ...
October 2025 Tezspire approved in the US for chronic rhinosinusitis with nasal polyps Approval broadens indication for Tezspire to a second disease characterised by epithelial-driven inflammationAstra ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback